Dr. Jimmy Chang, CEO of TaiMed Biologics, will deliver a presentation from 10:10 a.m. to 11:00 a.m., highlighting the Company's operating achievements, pipeline development, and long-term global growth strategy to domestic and international institutional investors.
During the forum, TaiMed will provide updates on its key development programs, including the latest progress and future development plans for the Phase II clinical trial of its long-acting bispecific antibody combination, TMB-365/TMB-380. The Company will also share recent developments regarding the global commercialization of Trogarzo® (ibalizumab-uiyk), including its regulatory and commercialization progress in Taiwan.
In addition, TaiMed will introduce its proprietary CD4-targeting antibody platform, highlighting its potential applications in HIV treatment and autoimmune diseases, as well as the Company's strategy for expanding its innovative product portfolio.
On the commercialization front, TaiMed will discuss the progress of its global licensing initiatives and emphasize that its Zhubei cGMP biologics manufacturing facility has successfully passed inspection by the U.S. Food and Drug Administration (FDA). The facility is fully compliant with international cGMP standards and is capable of supporting both clinical supply and future commercial manufacturing, further strengthening the Company's competitiveness in global partnerships and market expansion.
TaiMed stated that it remains committed to innovation-driven growth by leveraging its long-acting antibody technology platform, world-class manufacturing capabilities, and global licensing strategy. Through continued advancement of clinical development and commercialization, together with expansion into international markets, the Company aims to enhance long-term shareholder value and further establish itself as a globally competitive innovative biotechnology company.
Contact CDMO Service